[ad_1]
Roehrborn CG, Marks L, Harkaway R. Enlarged prostate: a landmark nationwide survey of its prevalence and affect on US males and their companions. Prostate Most cancers Prostatic Dis. 2006;9:30–4.
Egan KB. The epidemiology of benign prostatic hyperplasia related to decrease urinary tract signs: prevalence and incident charges. Urol Clin North Am. 2016;43:289–97.
Wei JT, Calhoun E, Jacobsen SJ. Urologic illnesses in America venture: benign prostatic hyperplasia. J Urol. 2008;179:S75–80.
Taub DA, Wei JT. The economics of benign prostatic hyperplasia and decrease urinary tract signs in the US. Curr Urol Rep. 2006;7:272–81.
Nickel JC, Aaron L, Barkin J, Elterman D, Nachabe M, Zorn KC. Canadian Urological Affiliation guideline on male decrease urinary tract signs/benign prostatic hyperplasia (MLUTS/BPH): 2018 replace. Can Urol Assoc J. 2018;12:303–12.
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Administration of decrease urinary tract signs attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical administration. J Urol. 2021;206:806–17.
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Administration of decrease urinary tract signs attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-surgical analysis and therapy. J Urol. 2021;206:818–26.
Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug adherence and medical outcomes for sufferers underneath pharmacological remedy for decrease urinary tract signs associated to benign prostatic hyperplasia: population-based cohort examine. Eur Urol. 2015;68:418–25.
Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to drugs for benign prostatic hyperplasia. J Urol. 2009;181:2214–21.
Roehrborn CG, Siami P, Barkin J, Damiao R, Main-Walker Ok, Nandy I, et al. The results of mixture remedy with dutasteride and tamsulosin on medical outcomes in males with symptomatic benign prostatic hyperplasia: 4-year outcomes from the CombAT examine. Eur Urol. 2010;57:123–31.
Alexander CE, Scullion MM, Omar MI, Yuan Y, Mamoulakis C, N’Dow JM, et al. Bipolar versus monopolar transurethral resection of the prostate for decrease urinary tract signs secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019;12:CD009629.
Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R. The affect of minimally invasive surgical procedures for the therapy of symptomatic benign prostatic hyperplasia on male sexual perform: a scientific assessment. Asian J Androl. 2010;12:500–8.
Zang YC, Deng XX, Yang DR, Xue BX, Xu LJ, Liu XL, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a scientific assessment with meta-analysis of randomized managed trials. Lasers Med Sci. 2016;31:235–40.
Sokolakis I, Pyrgidis N, Russo GI, Sountoulides P, Hatzichristodoulou G. Preserving ejaculation: a information via the panorama of interventional and surgical choices for benign prostatic obstruction. Eur Urol Focus. 2022. https://doi.org/10.1016/j.euf.2022.03.008.
Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic assessment of decrease urinary tract signs/benign prostatic hyperplasia surgical remedies on males’s ejaculatory perform: time for a bespoke method? Int J Urol. 2016;23:22–35.
Lokeshwar SD, Patel P, Shah SM, Ramasamy R. A scientific assessment of human trials utilizing stem cell remedy for erectile dysfunction. Intercourse Med Rev. 2020;8:122–30.
Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral carry for the therapy of decrease urinary tract signs related to prostate enlargement because of benign prostatic hyperplasia: the L.I.F.T. examine. J Urol. 2013;190:2161–7.
Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. 5 yr outcomes of the potential randomized managed prostatic urethral L.I.F.T. examine. Can J Urol. 2017;24:8802–13.
McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel Ok, Shore ND, et al. Minimally invasive prostate convective water vapor power ablation: a multicenter, randomized, managed examine for the therapy of decrease urinary tract signs secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529–38.
McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal remedy for decrease urinary tract signs related to benign prostatic hyperplasia: 4-year outcomes from randomized managed examine. Urology. 2019;126:171–9.
Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Massive, multi-center, potential registry of rezum water vapor remedy for benign prostatic hyperplasia. Urology. 2022. https://doi.org/10.1016/j.urology.2022.02.001.
Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Rezum remedy for >/=80-mL benign prostatic enlargement: a big, multicentre cohort examine. BJU Int. 2022. https://doi.org/10.1111/bju.15753.
Mollengarden D, Goldberg Ok, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal remedy for benign prostatic hyperplasia: a single workplace expertise. Prostate Most cancers Prostatic Dis. 2018;21:379–85.
Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgical procedure as preliminary remedy for sufferers with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness evaluation. BJU Int. 2018;122:879–88.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Suggestions for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in well being and drugs. JAMA. 2016;316:1093–103.
TreeAge Professional 2021, R1.0. TreeAge Software program, Williamstown, MA; Software program accessible at https://www.treeage.com.
Tanneru Ok, Jazayeri SB, Alam MU, Kumar J, Bazargani S, Kuntz G, et al. An oblique comparability of newer minimally invasive remedies for benign prostatic hyperplasia: a community meta-analysis mannequin. J Endourol. 2021;35:409–16.
Guo S, Muller G, Lehmann Ok, Talimi S, Bonkat G, Puschel H, et al. The 80-W KTP GreenLight laser vaporization of the prostate versus transurethral resection of the prostate (TURP): adjusted evaluation of 5-year outcomes of a potential non-randomized bi-center examine. Lasers Med Sci. 2015;30:1147–51.
Mattiasson A, Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, et al. 5-year follow-up of suggestions microwave thermotherapy versus TURP for medical BPH: a potential randomized multicenter examine. Urology. 2007;69:91–6.
Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Pure historical past of prostatism: longitudinal modifications in voiding signs in neighborhood dwelling males. J Urol. 1996;155:595–600.
McVary KT, Gittelman MC, Goldberg KA, Patel Ok, Shore ND, Levin RM, et al. Remaining 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal remedy for therapy of average to extreme decrease urinary tract signs secondary to benign prostatic hyperplasia. J Urol. 2021;206:715–24.
Bachmann A, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A European multicenter randomized noninferiority trial evaluating 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the therapy of benign prostatic obstruction: 12-month outcomes of the GOLIATH examine. J Urol. 2015;193:570–8.
Thomas JA, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A multicenter randomized noninferiority trial evaluating GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the therapy of benign prostatic obstruction: two-yr outcomes of the GOLIATH examine. Eur Urol. 2016;69:94–102.
Castellani D, Pirola GM, Rubilotta E, Gubbiotti M, Scarcella S, Maggi M, et al. GreenLight laser photovaporization versus transurethral resection of the prostate: a scientific assessment and meta-analysis. Res Rep Urol. 2021;13:263–71.
Teng J, Zhang D, Li Y, Yin L, Wang Ok, Cui X, et al. Photoselective vaporization with the inexperienced gentle laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a scientific assessment and meta-analysis. BJU Int. 2013;111:312–23.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr., Dixon CM, Kusek JW, et al. The long-term impact of doxazosin, finasteride, and mixture remedy on the medical development of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.
Arias E, Xu J. Nationwide Very important Statistics Stories. United States Life Tables, 2018. Vol. 69, Quantity 12, p. 45. Facilities for Illness Management and Prevention; 2020.
Baladi JF, Menon D, Otten N. An financial analysis of finasteride for therapy of benign prostatic hyperplasia. Pharmacoeconomics. 1996;9:443–54.
Ackerman SJ, Rein AL, Blute M, Beusterien Ok, Sullivan EM, Tanio CP, et al. Value effectiveness of microwave thermotherapy in sufferers with benign prostatic hyperplasia: half I-methods. Urology. 2000;56:972–80.
Liu H, Harris KM, Weinberger S, Serxner S, Mattke S, Exum E. Impact of an employer-sponsored well being and wellness program on medical value and utilization. Popul Well being Manag. 2013;16:1–6.
US Facilities for Medicare and Medicaid Providers. Medicare half D drug spending dashboard & information. 2021. https://www.cms.gov/Analysis-Statistics-Information-and-Techniques/Statistics-Traits-and-Stories/Data-on-Prescription-Medicine/MedicarePartD.
Black L, Naslund MJ, Gilbert TD, Davis AE, Ollendorf DA. An examination of therapy patterns and prices of care amongst sufferers with benign prostatic hyperplasia. Am J Manag Care. 2006;12:S99–110.
Chughtai B, Rojanasarot S, Neeser Ok, Gultyaev D, Amorosi SL, Shore ND. Value-effectiveness and price range affect of rising minimally invasive surgical remedies for benign prostatic hyperplasia. J Well being Econ Outcomes Res. 2021;8:42–50.
Nationwide Institue for Well being and Care Excellence. Rezum for treating decrease urinary tract signs secondary to benign prostatic hyperplasia. Medical applied sciences steering. 2020. www.good.org.uk.steering/mtg49.
Ulchaker JC, Martinson MS. Value-effectiveness evaluation of six therapies for the therapy of decrease urinary tract signs because of benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43.
Robert G, Cornu JN, Fourmarier M, Saussine C, Descazeaud A, Azzouzi AR, et al. Multicentre potential analysis of the training curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016;117:495–9.
Robles J, Pais V, Miller N. Thoughts the gaps: adoption and underutilization of holmium laser enucleation of the prostate in the US from 2008 to 2014. J Endourol. 2020;34:770–6.
US Facilities for Medicare and Medicaid Providers. FY 2019 IPPS Remaining Rule Residence Web page. 2021. https://www.cms.gov/Medicare/Medicare-Charge-for-Service-Cost/AcuteInpatientPPS/FY2019-IPPS-Remaining-Rule-Residence-Web page-Gadgets/FY2019-IPPS-Remaining-RuleTables.html.
[ad_2]
